Reports Q4 revenue $1.03B, consensus $1.02B. “2023 was an incredible year for Dexcom with significantly expanded access, another year of record new customer starts, and growing momentum behind our global rollout of Dexcom G7,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “We are looking forward to another great year in 2024 as we strive to improve the health of significantly more people around the world with Dexcom CGM technology.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXCM:
- DXCM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- DexCom price target raised to $140 from $137 at Canaccord
- DexCom breaks ground on new manufacturing facility in Ireland
- DexCom price target raised to $145 from $136 at Wells Fargo
- DexCom sees FY24 revenue $4.15B-$4.35B, consensus $4.32B